Bear Stearns ups estimates for Merck

Bear Stearns analyst John Boris rated Merck & Co., Inc. at peer perform and raised estimated earnings per share to $2.52 (up 6%), $2.62 (up 4%) and $2.72 (up 4%) for 2006, 2007 and 2008, respectively. Merck is transitioning from regulatory risk to commercialization risk, with six new product approvals, according to the analyst. Look for the launches of Gardasil and Januvia as important contributors to the company's incremental revenue. Shares of the Whitehouse Station, N.J., pharmaceutical company were up 6 cents, or 0.13%, at $45.70. (NYSE: MRK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.